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vancomycin and daptomycin. Second line intravenous daptomycin was assumed 
to be administered via an outpatient parenteral treatment service. ConClusions: 
Findings suggest that use of first-line linezolid in the management of MRSA-cSSTIs 
could result in savings for the third-party payer in Greece accompanied by enhanced 
quality of life results.
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objeCtives: The United Kingdom (UK) has a targeted hepatitis B (HBV) vaccination 
programme for at-risk patient groups; however such a programme can be challeng-
ing to implement. The World Health Organisation (WHO) recommends universal 
HBV vaccination and this approach has been adopted by most developed countries. 
A systematic review was conducted to identify UK-based mathematical models for 
HBV to determine whether current evidence supports the use of a universal vaccina-
tion programme versus a targeted approach. Methods: Embase, Medline, Econlit 
and The Cochrane Library were searched for studies reporting HBV mathematical 
models (economic or epidemiological) in the UK population. Hand searching of 
Health Protection Agency and National Institute for Health and Clinical Excellence 
guidance documents was also performed. Economic models (cost-effectiveness, 
cost-utility, cost-benefit, cost-consequence) were included if they assessed HBV 
vaccination or screening programmes. Epidemiological studies were included if they 
modelled HBV immunity and infection rates. Data were independently extracted 
and summarised into evidence tables by two reviewers and quality appraisal of 
included studies was performed. Results: Electronic database searches identified 
a total of 649 citations resulting in 11 relevant publications. Hand searching yielded 
an additional two publications; a total of 13 included publications representing 
seven economic evaluations and six epidemiological modelling studies. Overall, 
there was considerable variation in model methodologies including methods of 
discounting used, static versus dynamic approaches and sources of model inputs. 
Only one epidemiological modelling study considered HBV transmission patterns 
across the UK. ConClusions: Current HBV vaccination policy in the UK is depend-
ent on the demonstration of cost-effectiveness. However, this review highlights 
some of the limitations inherent in the models which have been used to support 
policy decisions. Alternative modelling approaches, as well as new data on key 
inputs, are desirable if the full value of a universal HBV vaccination programme in 
the UK is to be assessed.
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objeCtives: Today vaccination for children from 0 to 20 months in the Russian 
Federation is carried mainly by DPT and monovalent vaccines. As a result, a child 
of this age receives 12 injections. Vaccination against Hib infection so far is only 
available for children at risk (approx. 20%). Introdution of DTaP-IPV-Hib combined 
vaccine could reduce the number of injections received by the child and increase 
the coverage against Hib infection from 20% to 97%. The objective of the present 
study is to assess the economic evaluation of DTaP-IPV-Hib vaccine introduction 
into immunization schedule and select the most cost-effective vaccination scheme 
against Hib infection. Methods: A cost-effectiveness analysis of the DTaP-IPV-Hib 
vaccine is performed on suggested Markov model. The four vaccination schemes are 
intercompared : the current immunization program (Scheme0), a 3+1 immuniza-
tion DTaP-IPV-Hib vaccine (Scheme P), a mixed DTwP /DTaP-IPV-Hib immunization 
(Scheme mix) and a potential scenario - the current scheme, but with expanded 
(97%) Hib coverage - Scheme 1. The cohort of infants born in 2011 year is followed 
over their lifetime. Direct and indirect medical costs are measured from the perspec-
tive of the public payer. Outcomes are measured in life years gained (LYG).Exchange 
rate is 1€ = 41 rub. Results: According to the model, total costs of immunization 
Scheme are: 0 – 4216723519 rub. (102 846 915€ ), Scheme 1 –4924823829 rub.(120 117 
654€ ), Scheme P -6035132925rub.(147 198 364€ ), Scheme mix - 4 921 824 835 rub 
(120 044 508€ ). The values of cost/LYG are estimated at 4243 198 rub .(103493€ ) for 
Scheme 0, 1 224 270rub.(29860€ )for Scheme 1, 1500 283 rub. (36592€ ) for Scheme P, 
1223 525rub.(29842€ )– for Scheme mix. ConClusions: The introduction of DTaP-
IPV-Hib combined vaccine would bring improvement into the Russian immunization 
program through a Scheme mix.
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objeCtives: To evaluate the impact of different discounting approaches on economic 
evaluation using an example of Hepatitis B model. Currently, constant discounting 
rates of 3.5% are applied for costs and outcomes in the UK. This study applied different 
approaches such as empirical, stepwise and time-shifted discounting in parallel to 
the constant discounting to identify their respective impact on the cost-effectiveness 
results with respect to the NICE threshold. Methods: To compare costs and out-
comes of a vaccination policy, a Markov model was built for the UK population birth 
cohort. Patients entered after contracting Hepatitis B and were followed until 80 years 
old. The health states included chronic carrier phase, immune, compensated and 
decompensated cirrhosis, hepatocellular carcinoma and death. The different dis-
counting approaches were applied to the costs and health outcomes. The Incremental 
Cost-Effectiveness Ratios (ICERs) thus obtained were compared. Results: The ICER 
obtained was higher than the NICE threshold of £20,000 to £30,000 per QALY gained 
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objeCtives: Approximately 1.1 million people in the U.S. are living with HIV, with 
50,000 new infections per year. The FDA approved Stribild™, a once-daily HIV medi-
cation, in September of 2012. The primary objective of this study was to assess 
the cost and disease-related outcomes of Stribild versus guideline-recommended 
treatment options for HIV patients in a specialty retail pharmacy. A secondary objec-
tive was to assess compliance via Medication Possession Ratios (MPRs). Methods: 
HIV patients who were prescribed one of five antiretroviral regimens in the period 
from January 1, 2010 to June 21, 2013 and who obtained their medications through 
Schnucks Specialty Pharmacy were selected via a retrospective chart review. By 
measuring the direct cost of the medications to the pharmacy and the disease-
related outcomes, change in CD4 count and viral load suppression, the cost-effec-
tiveness of Stribild versus its comparators was assessed. Results: A total of 92 
patients were included in this study: 50 Stribild patients and 42 patients on alternate 
regimens: 15 Atripla®; 6 Isentress®; 10 Prezista®; and 11 Reyataz®. Incremental Cost-
Effectiveness Ratios (ICERs) were conducted between Stribild and the comparators 
for change in mean CD4 count and percent viral load suppression (< 20 copies/ml) 
achieved. In terms of CD4 count, Stribild was most cost-effective when compared 
to Prezista and least cost-effective when compared to Isentress. Analyses of viral 
load suppression indicated that Stribild is more cost-effective than Prezista and 
Reyataz but less cost-effective than Atripla or Isentress. Mean MPR was greater 
than 95% for Stribild and three of its comparators (not including Atripla); however, 
78 percent of Stribild patients achieved MPR ≥ 95% which demonstrates higher 
compliance than all comparators except the Isentress patients. ConClusions: 
The once-daily regimen Stribild appears effective at treating the HIV virus while 
maintaining compliance for most of its patients; its high cost remains a concern 
for formulary decision makers.
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objeCtives: To estimate the cost-effectiveness of antimicrobials (ceftaroline, 
linezolid and vancomycin) as treatment for patients with complicated skin and 
soft tissues infections. Methods: A literature-based cost-effectiveness analysis 
was developed to estimate the costs of complicated skin and soft tissues infec-
tions patients initiating therapy with ceftaroline, linezolid or vancomycin. Direct 
expenses associated with complicated skin and soft tissues infections and resulting 
follow-up costs were calculated using general tariff agreement of Russian obligatory 
insurance system and official national statistics. For reference, accepted exchange 
rate was 1 EUR = 40 RUB. Results: Compared to ceftaroline, linezolid or vanco-
mycin results in increases in drug therapy costs: 77 997 RUB (1 950 EUR) per patient 
in ceftaroline group (therapy duration – 9 days), 78 816 RUB (1 970 EUR) per patient 
in vancomycin group (therapy duration – 10 days) and 117 893 RUB (2 947 EUR) per 
patient in linezolid group (therapy duration – 12 days). The values of cost/clinical 
cure rate are estimated at 96 055 RUB (2 401 EUR) in ceftaroline group, 98 030 RUB (2 
451 EUR) in vancomycin group, and 138 860 RUB (3 472 EUR) in linezolid group per 
patient. ConClusions: The results of cost-effectiveness illustrate that ceftaroline 
is dominant in Russian patients with complicated skin and soft tissues infections 
who are initiating antimicrobials therapy compared with linezolid or vancomycin.
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objeCtives: Meticillin-resistant staphylococcus aureus (MRSA) is an important 
cause of antimicrobial-resistant health care-associated infections worldwide. Its 
prevalence remains high in the Greek hospital setting. Complicated skin and soft tis-
sue infections (cSSTIs) due to MRSA are associated with prolonged hospitalization, 
additional costs of care and significant morbidity. The purpose of this study was to 
conduct a cost-effectiveness analysis of different treatment scenarios in the man-
agement of MRSA-cSSTIs, under a third-party payer perspective. Methods: The 
model was based on a decision tree simulating costs and outcomes for a maximum of 
28 days, consisting of empiric, first-line and second-line treatment, for patients with 
MRSA-cSSTIs. Inpatient and outpatient health care services were included in the 
analysis. Data on efficacy of the pharmacotherapies under evaluation were derived 
from a recent meta-analysis (Bassetti et al 2013) and resource use was elicited via 
an expert panel. Economic results, expressed in Euros (2013), reflect the Greek social 
insurance setting. Results: Three different first→second line treatment scenarios 
(daptomycin→linezolid, linezolid→daptomycin, vancomycin→linezolid) were evalu-
ated, as recommended by the expert panel. Total management costs per patient 
were € 4,199, € 3,809, and € 3,900; quality adjusted life years (QALY) gained were 0.058, 
0.059 and 0.057 respectively for the above scenarios. The scenario containing first-
line linezolid proved to be a dominant therapeutic option vs. the other scenarios 
(less costly, higher QALYs), whereas first-line daptomycin scenario did not appear 
to be cost-effective vs. the respective vancomycin scenario (incremental cost-utility 
ratio € 243,932) in the management of MRSA-cSSTIs. Second line oral linezolid was 
used as continuation treatment after failure/intolerance or switch from intravenous 
